HiTech delivers 16% profit growth

Published 15-AUG-2018 13:05 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Name: HiTech Group Australia (ASX:HIT)

Market Capitalisation: $46 million

Closing Share Price: $1.18 (Current share price ($1.10)

After delivering profit growth of 16% for fiscal 2018, shares in HiTech Group hit a 12 month high of $1.18, and they closed at that level on Monday. Management declared a final dividend of 4 cents per share, bringing the full year dividend to 8 cents per share, representing an attractive yield of 6.8% relative to Monday’s closing price.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

Consensus forecasts indicate that the full year dividend will increase to 9 cents per share in fiscal 2019, implying a yield of 7.6%.

The company provides both permanent and contract staff from its recruitment database of 340,000 specialised information and communications technology professionals.

The HiTech client base, of over 490 active clients, is well established, with strong representation by prominent technology companies and banking/financial services companies, as well as Federal Government departments and agencies.

HiTech has also entered into preferred supplier agreements for the supply of staff in both the public and private sectors.

Permanent recruitment, which comprises the search and selection of candidates for full time employment, is characterised by high profit margins.

Management has been and will continue to develop this side of the business as demand improves.

ICT contracting, comprising the provision of ICT professionals for temporary and other non-permanent staffing needs of clients for specific projects, has continued to supply HiTech with steady cash flow.

However, it is a relatively high volume business with lower margins relative to permanent recruitment revenue.

There is a place for both types of business, and management continues to grow the contract business, with a view to generating increased revenue, even though it offers lower margins.

Revenue targets are speculative, so investors should seek professional financial advice for further information if considering this stock for their portfolio.

Having finished the year with cash of $5.8 million, representing an increase of 13% compared with the previous corresponding period, management could choose to grow either business segment through acquisitions.

It also provides the capacity to sustain a robust dividend stream.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free